Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

Non–small cell lung cancers (NSCLCs) that harbor mutations within the epidermal growth factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. Unfortunately, all patients treated with these drugs will acquire resistance, most commonly as a result o...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Chmielecki, Juliann, Foo, Jasmine, Oxnard, Geoffrey R., Hutchinson, Katherine, Ohashi, Kadoaki, Somwar, Romel, Wang, Lu, Amato, Katherine R., Arcila, Maria, Sos, Martin L., Socci, Nicholas D., Viale, Agnes, de Stanchina, Elisa, Ginsberg, Michelle S., Thomas, Roman K., Kris, Mark G., Inoue, Akira, Ladanyi, Marc, Miller, Vincent A., Michor, Franziska, Pao, William
Формат: Artigo
Язык:Inglês
Опубликовано: 2011
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500629/
https://ncbi.nlm.nih.gov/pubmed/21734175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3002356
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы